Frank Damelio Buys 6,650 Shares of Zoetis (NYSE:ZTS) Stock

Zoetis Inc. (NYSE:ZTS) Director Frank Damelio bought 6,650 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the acquisition, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. This represents a 44.91% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Zoetis Stock Performance

Zoetis stock traded down $2.62 during midday trading on Wednesday, hitting $74.32. The stock had a trading volume of 12,797,540 shares, compared to its average volume of 4,968,603. The firm’s fifty day moving average is $115.42 and its two-hundred day moving average is $122.28. The company has a market capitalization of $31.16 billion, a PE ratio of 12.33, a P/E/G ratio of 1.25 and a beta of 0.87. Zoetis Inc. has a 52-week low of $74.29 and a 52-week high of $172.23. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same period in the prior year, the company posted $1.48 earnings per share. The company’s revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.9 EPS for the current year.

Institutional Trading of Zoetis

A number of institutional investors have recently bought and sold shares of ZTS. Brighton Jones LLC lifted its position in Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares during the last quarter. Empowered Funds LLC lifted its position in Zoetis by 6.2% in the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after buying an additional 657 shares during the last quarter. Intech Investment Management LLC increased its stake in Zoetis by 17.2% in the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares during the period. Sivia Capital Partners LLC increased its stake in Zoetis by 73.8% in the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after purchasing an additional 1,422 shares during the period. Finally, Glenview Trust co increased its stake in Zoetis by 11.8% in the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after purchasing an additional 506 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Bank of America increased their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. Stifel Nicolaus set a $105.00 price objective on shares of Zoetis in a report on Friday, May 8th. Citigroup began coverage on Zoetis in a research report on Wednesday, April 15th. They set a “buy” rating and a $145.00 target price for the company. Piper Sandler reiterated a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Finally, UBS Group lowered their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Zoetis presently has an average rating of “Hold” and a consensus target price of $141.25.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.